NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb. 12, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Acting Chief Financial Officer, will participate in one-on-ones with investors and business development meetings with biopharmaceutical executives at the BIO CEO & Investor Conference, taking place February 26-27, 2024 in New York.
馬薩諸塞州劍橋，2024 年 2 月 12 日 /PRNewswire/-- NeuroBo 製藥公司 納斯達克股票代碼：NRBO）是一家專注於改變心臟代謝疾病的臨床階段生物技術公司，今天宣佈，總裁兼首席執行官金亨憲和代理首席財務官馬歇爾·伍德沃思將在2024年2月26日至27日在紐約舉行的BIO首席執行官兼投資者會議上與投資者進行一對一的會談以及與生物製藥高管的業務發展會議。
Interested parties can request a meeting through the BIO One-on-One Partnering System:
感興趣的各方可以通過BIO一對一合作系統申請會議：
To schedule a meeting with management outside of the conference, please contact Michael Miller at [email protected].
要安排在會議之外與管理層會面，請通過 [email protected] 與邁克爾·米勒聯繫。
About NeuroBo Pharmaceuticals
關於 NeuroBo 製藥
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.
NeuroBo Pharmaceuticals, Inc. 是一家臨床階段的生物技術公司，專注於改變心臟代謝疾病。該公司目前正在開發用於治療代謝功能障礙相關性脂肪肝炎 (MASH) 和 2 型糖尿病 (T2DM) 的 DA-1241，並正在開發用於治療肥胖的 DA-1726。DA-1241 是一種新型 G 蛋白偶聯受體 119 (GPR119) 激動劑，可促進關鍵腸道肽 GLP-1、GIP 和 PYY 的釋放。在臨床前研究中，DA-1241 顯示出對肝臟炎症、脂質代謝、體重減輕和葡萄糖代謝具有積極作用，可減少肝臟脂肪變性、肝炎和肝纖維化，同時還改善了血糖控制。DA-1726 是一種新型的氧調節素 (OXM) 類似物，可用作胰高血糖素樣肽 1 受體 (GLP1R) 和胰高血糖素受體 (GCGR) 雙重激動劑。OXM 是一種天然存在的腸道激素，可激活 GLP1R 和 GCGR，從而減少食物攝入量，同時增加能量消耗，因此與選擇性的 GLP1R 激動劑相比，有可能顯著減輕體重。
For more information, please visit .
欲了解更多信息，請訪問。
Contact:
聯繫人：
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Interim Chief Financial Officer
+1-857-299-1033
[email protected]
紐羅博製藥
馬歇爾·H·伍德沃思
臨時首席財務官
+1-857-299-1033
[電子郵件保護]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Rx 通信組
邁克爾·米勒
+1-917-633-6086
[電子郵件保護]
SOURCE NeuroBo Pharmaceuticals, Inc.
來源 NeuroBo 製藥公司
譯文內容由第三人軟體翻譯。